Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.97

€1.97

-3.920%
-0.074
-3.920%
€24.93

€24.93

 
27.03.24 / Tradegate WKN: A3DMG4 / Symbol: AEZS / Name: AEterna Zentaris / Stock / Biotechnology & Medical Research / Micro Cap /
Latest predictions
22.03.24
8.00%
16.03.24
2.07%
buy
13.03.24
2.69%
18.02.24
11.85%
10.02.24
19.37%
01.01.24
14.25%
Your prediction

AEterna Zentaris Inc. Stock

AEterna Zentaris Inc. took a tumble today and lost -€0.074 (-3.920%).
Our community is currently low on AEterna Zentaris Inc. with 4 Buy predictions and 18 Sell predictions.
However, we have a potential of 1117.04% for AEterna Zentaris Inc. as the target price of 24 € is above the current price of 1.97 €.
For the coming years our community has positive and negative things to say abot the AEterna Zentaris Inc. stock. Criterium "Innovation" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.

Pros and Cons of AEterna Zentaris Inc. in the next few years

Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of AEterna Zentaris Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
AEterna Zentaris Inc. -3.920% 0.921% 13.725% -19.180% 12.944% -92.523% -97.902%
StageZero Life Sciences Ltd. 13.210% 12.766% 15.217% -59.848% 17.778% - -
Satellos Bioscience Inc. 4.110% -11.515% -34.234% 2.277% 5.797% -77.188% -
Antibe Therapeutics Inc. - 3.333% -61.550% -28.736% -52.762% -92.619% -85.747%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-26

Upon examining the financial health of AEterna Zentaris, a player in the biotechnology and medical research industry, the immediate observation is that this company paints a picture of considerable financial challenges. With a modest market capitalization of approximately $8.61 million and an EBITDA which stands at a negative $15.70 million, one can infer that the company’s earnings before interest, taxes, depreciation, and amortization are not sufficient to cover these expenses, implying operational difficulties.

With a deep dive into the details, let us first elucidate the strengths or potential upsides in AEterna Zentaris' financial situation:

Conversely, a comprehensive analysis reveals a more extensive list of concerns:

Comments

Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for AEZS provided by MarketBeat
Show more

Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for AEZS provided by MarketBeat
Show more

Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for AEZS provided by MarketBeat
Show more